LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

Search

MacroGenics Inc

Затворен

СекторЗдравеопазване

1.71 -2.29

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.67

Максимум

1.78

Ключови измерители

By Trading Economics

Приходи

4.8M

-36M

Продажби

9M

22M

Марж на печалбата

-162.992

Служители

341

EBITDA

5.7M

-33M

Препоръки

By TipRanks

Препоръки

Неутрален

12-месечна прогноза

+155.68% upside

Дивиденти

By Dow Jones

Следващи печалби

4.11.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

19M

112M

Предишно отваряне

4

Предишно затваряне

1.71

Настроения в новините

By Acuity

75%

25%

346 / 371 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Neutral Evidence

MacroGenics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

8.09.2025 г., 23:59 ч. UTC

Придобивния, сливания и поглъщания

Anglo American Is in Talks to Buy Teck Resources, Bloomberg Says

8.09.2025 г., 22:02 ч. UTC

Значими двигатели на пазара

Microsoft Signs $17.4 Billion AI Deal With Nebius

8.09.2025 г., 17:01 ч. UTC

Значими двигатели на пазара

Eightco Holdings Stock Surges as Dan Ives Joins Board Amid Crypto Push

8.09.2025 г., 17:01 ч. UTC

Значими двигатели на пазара

Tron Shares Rise After New Investment From Bravemorning

8.09.2025 г., 16:14 ч. UTC

Значими двигатели на пазара

Beyond Air Shares Climb on FDA Orphan Drug Designation for Brain Cancer Treatment

8.09.2025 г., 16:13 ч. UTC

Значими двигатели на пазара

Dianthus Shares Whipsaw on Strong Trial Results, Safety Concerns

8.09.2025 г., 23:12 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

8.09.2025 г., 23:12 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

8.09.2025 г., 23:12 ч. UTC

Пазарно говорене

Infratil's New Bull Likes Exposure to Growing Infrastructure Businesses -- Market Talk

8.09.2025 г., 22:56 ч. UTC

Пазарно говорене

Worst May Be Over for New Zealand Retailers -- Market Talk

8.09.2025 г., 22:23 ч. UTC

Пазарно говорене

Ebos's Near-Term Earnings Outlook Dims -- Market Talk

8.09.2025 г., 21:51 ч. UTC

Пазарно говорене

AT&T Backs Outlook After EchoStar Spectrum Purchase -- Market Talk

8.09.2025 г., 21:47 ч. UTC

Значими двигатели на пазара

Microsoft Signs $17.4B AI Deal With Nebius

8.09.2025 г., 21:33 ч. UTC

Придобивния, сливания и поглъщания

This Quantum Pure Play Is Going Public. What Infleqtion Does Differently, Says Its CEO. -- Barrons.com

8.09.2025 г., 21:20 ч. UTC

Придобивния, сливания и поглъщания

MEG Energy Plans to Respond on or Before Sept 15 >MEG.T

8.09.2025 г., 21:19 ч. UTC

Придобивния, сливания и поглъщания

MEG Energy Special Committee and Board Will Evaluate Revised Strathcona Offer >MEG.T

8.09.2025 г., 21:18 ч. UTC

Придобивния, сливания и поглъщания

MEG Energy Acknowledges Strathcona's Intention to Revise Offer

8.09.2025 г., 20:50 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Tech, Media & Telecom Roundup: Market Talk

8.09.2025 г., 19:33 ч. UTC

Пазарно говорене

Oil Futures Gain Despite Planned OPEC+ Output Increases -- Market Talk

8.09.2025 г., 19:22 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Settle Higher -- Market Talk

8.09.2025 г., 19:02 ч. UTC

Пазарно говорене

Dollar Lukewarm Amid Data Hiatus Ahead of August CPI -- Market Talk

8.09.2025 г., 18:24 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

8.09.2025 г., 18:24 ч. UTC

Пазарно говорене

Weaker Argentine Peso Profitable for Grain Producers -- Market Talk

8.09.2025 г., 17:29 ч. UTC

Пазарно говорене

Mexican Inflation Seen Little Changed in August -- Market Talk

8.09.2025 г., 16:59 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

SpaceX Spectrum Acquisition Will Create More Satellite Connection Supply, Verizon CEO Says -- Market Talk

8.09.2025 г., 16:36 ч. UTC

Пазарно говорене

Crude Futures Hold Gains After OPEC+ Output Decision -- Market Talk

8.09.2025 г., 16:20 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

8.09.2025 г., 16:16 ч. UTC

Печалби

Strategy Stock May Not Ever Make It Into the S&P 500 Index -- Barrons.com

8.09.2025 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

8.09.2025 г., 16:04 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

MacroGenics Inc Прогноза

Ценова цел

By TipRanks

155.68% нагоре

12-месечна прогноза

Среден 4.5 USD  155.68%

Висок 5 USD

Нисък 4 USD

Според 4 анализатори от Wall Street, предложили 12-месечна ценова цел за MacroGenics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

4 ratings

1

Купи

3

Задържане

0

Продай

Техническа оценка

By Trading Central

1.47 / 1.64Подкрепа & съпротива

Краткосрочен план

Neutral Evidence

Средносрочен план

Bullish Evidence

Дългосрочен план

Bearish Evidence

Настроение

By Acuity

346 / 371 Класиране в Здравеопазване

Настроения в новините

Много силни мечи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
help-icon Live chat